32
total announcements
SANOFI.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 21 Oct 2026
Market Cap
₹6,634 Cr
P/E (TTM)
20.5
P/E (Forward)
16.1
EPS (TTM)
₹140.59
52W Low
₹2,875.10
52W High
₹4,898.00
Dividend Yield
4.27%
Beta
0.16
Price / Book
8.0
Return on Equity
40.27%
Debt / Equity
1.8
Revenue (TTM)
₹1,805 Cr
Gross Margin
49.01%
Operating Margin
24.31%
Sanofi India Limited
Sanofi India Limited has received a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities for the quarter ended 30th September 2026.
Sanofi India Limited
Sanofi India Limited has received a Show Cause Notice from the State Tax Officer Ghatak 21 (Ahmedabad) Range 6 Division 2, Gujarat, alleging discrepancies in GST matters pertaining to FY 2022-23. The notice proposes a tax, interest, and penalty demand aggregating to Rs.16,40,07,641. The company is in the process of responding to the notice and does not envisage any adverse impact on its financials, operations, or other activities.
Sanofi India Limited
Sanofi Healthcare India Private Limited, a part of the promoter group of Sanofi India Limited, has acquired 3,500,000 equity shares representing 15.20% of the equity share capital of Sanofi India Limited from Hoechst GmbH, a promoter of the Target Company, through a block deal mechanism on the Stock Exchange.
Sanofi India Limited
Sanofi India Limited has made a disclosure under Regulation 7(2)(a) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, regarding the purchase of equity shares by Sanofi Healthcare India Private Limited, an entity of the Promoter Group, from Hoechst GmbH, a Promoter of the Company, through a block deal mechanism on the Stock Exchange.
Sanofi India Limited
Sanofi India Limited has informed the Exchange regarding 'Disclosure Under Regulation 7(2)(B) Of The SEBI (Prohibition Of Insider Trading) Regulations, 2015'. The company has received a disclosure from Hoechst GmbH, a Promoter, regarding the disposal of equity shares by way of transfer to Sanofi Healthcare India Private Limited, an entity of the Promoter Group, through a block deal mechanism on the Stock Exchange.
Sanofi India Limited
Sanofi India Limited has received a Show Cause Notice from the Commercial Tax Officer (Audit) under Section 73 of the Karnataka Goods and Services Tax Act, 2017, alleging excess claim of Input Tax Credit for FY 2022-23, with a proposed tax liability of Rs. 23,73,76,507.
Sanofi India Limited
Sanofi India Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Sanofi India Limited
Sanofi India Limited has disclosed an order issued by the State Tax Officer, Tiruvallur Assessment Circle, accepting the company's submissions and dropping a total tax demand of Rs. 1,06,78,760/- along with interest and penalty for FY 2022-23.
Sanofi India Limited
Sanofi Healthcare India Private Limited, a part of the promoter group of Sanofi India Limited, has agreed to acquire up to 3,500,000 equity shares from Hoechst GmbH, a promoter, under Regulation 10(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Sanofi India Limited
Sanofi India Limited has informed that the Hon'ble Supreme Court of India has dismissed the company's petition seeking quashing of the criminal proceedings against the company in a case related to pharmaceutical supplies made to Bhabha Atomic Research Centre between 2012 to 2015.
Sanofi India Limited
Sanofi India Limited has received a Show Cause Notice from the Additional Commissioner of CGST and CX, Mumbai East, alleging misclassification of certain products at a concessional rate of 5% instead of 12% for the financial year 2020-21, resulting in a proposed tax liability of Rs. 36,38,70,979 and a proposed penalty of Rs. 36,38,70,979. The company is in the process of responding to the notice and does not envisage any adverse impact on its financials, operations, or other activities.
Sanofi India Limited
Sanofi India Limited has submitted a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding an order passed by the Deputy Commissioner, Central Goods & Service Tax, Division –IV, Margao–Goa, which has accepted and sanctioned a GST refund of Rs.1,32,93,535.
Sanofi India Limited
Sanofi India Limited has disclosed an order passed by the Assistant Commissioner of Income Tax, TDS OSD TDS Circle 2(2), Mumbai, giving effect to a favourable action taken by the Commissioner of Income Tax Appeal (CIT(A)) - 49, Mumbai, for AY 2019-20, dropping the proceedings initiated under Section 201 of the Income-tax Act, 1961, thereby deleting the demand of Rs. 72,71,511.
Sanofi India Limited
Sanofi India Limited has announced its unaudited financial results for the quarter and half year ended 30th June 2026, with a strong momentum in the diabetes business, driven by double-digit growth in the domestic market, powered by innovative portfolio, Toujeo and Soliqua. The company has also reported a 2% growth in quarter two over last year's quarter two, based on the continued ROI from partnership with Emcure and Cipla.
Sanofi India Limited
Sanofi India Limited has informed the Exchange about the link of video recording of investor/analysts call for update on unaudited financial results for the quarter and half year ended 30th June 2026.
Sanofi India Limited
Sanofi India Limited has published its unaudited financial results for the quarter and half year ended 30th June 2026, showing a net profit of ₹57.60 crore and a total comprehensive income of ₹44.74 crore.
Sanofi India Limited
Sanofi India Limited has informed the Exchange about Investor / Analysts Call - Presentation for Q2/26 results, highlighting strong momentum in diabetes business with 8% growth, driven by innovative portfolio and partnerships.
Sanofi India Limited
Sanofi India Limited has announced its Q2 2026 financial results, reporting 8% domestic net sales growth and 6% total net sales growth compared to the second quarter of 2025. The company's insulin portfolio delivered double-digit growth of 14% for the second consecutive quarter, driven by strong sales of Lantus, Toujeo, and Apidra. Profits before tax and exceptional items increased 19% to INR 112 crores, with profit before tax as a percentage of net sales improving to 27%.
Sanofi India Limited
Sanofi India Limited has informed the Exchange about Re-constitution of the Committees of the Company. The Board of Directors at its meeting held today, considered and approved the Unaudited Financial Results for the quarter and half year ended 30th June 2026. The company reported domestic net sales growth of 8% and total net sales growth of 6% compared to the second quarter of 2025. The Insulin portfolio delivered double-digit growth of 14% for the second consecutive quarter.
Sanofi India Limited
Sanofi India Limited has announced its Q2 2026 financial results, reporting 8% domestic net sales growth and 6% total net sales growth compared to Q2 2025. The company's insulin portfolio delivered double-digit growth of 14%, driven by strong performance of Lantus, Toujeo, and Apidra. Profits before tax and exceptional items increased 19% to INR 112 crores, with profit before tax as a percentage of net sales improving to 27%.